Being Rh negative in pregnancy means your red blood cells lack a specific protein called the Rh factor, and about 15% of people fall into this category. On its own, being Rh negative is completely harmless. It only becomes a concern during pregnancy if your baby inherits Rh-positive blood from the father, because your immune system can recognize the baby’s blood cells as foreign and mount an attack against them. The good news: a simple, highly effective injection given during pregnancy prevents this from happening in the vast majority of cases.
What the Rh Factor Actually Is
The Rh factor (short for Rhesus factor) is a protein that sits on the surface of red blood cells. If you have it, your blood type is classified as positive (A+, B+, O+, etc.). If you don’t, you’re negative. Roughly 85% of people are Rh positive, making Rh-negative blood the less common type. You inherit your Rh status from your parents in a dominant pattern, meaning a baby only needs one copy of the gene from either parent to be Rh positive.
Why Rh Negative Matters in Pregnancy
The problem arises when an Rh-negative mother carries an Rh-positive baby. During pregnancy and especially during delivery, small amounts of the baby’s blood can cross into the mother’s bloodstream. When that happens, the mother’s immune system detects the Rh protein on those fetal blood cells and treats it as an invader, producing antibodies against it. This process is called sensitization.
Here’s the critical detail: the first exposure usually isn’t dangerous. The initial antibodies the body produces are large molecules that can’t cross the placenta to reach the baby. But the immune system has a long memory. During a second pregnancy with another Rh-positive baby, the mother’s body launches a much faster, stronger response, producing smaller antibodies that do cross the placenta. These antibodies attach to the baby’s red blood cells and destroy them.
Once this antibody production starts, it’s irreversible. Each subsequent pregnancy with an Rh-positive baby triggers an even larger wave of antibodies, making the risk more severe with every pregnancy.
What Can Happen to the Baby
When maternal antibodies cross the placenta and attack fetal red blood cells, the result is called hemolytic disease of the fetus and newborn. The severity varies widely. Some babies show no symptoms at all. Others develop serious, life-threatening complications.
The most common effects are anemia (from red blood cells being destroyed faster than the baby can replace them) and jaundice (from the buildup of bilirubin, a waste product released when red blood cells break down). In newborns, jaundice from Rh disease appears within the first 24 hours after birth and tends to be more severe than the mild jaundice many healthy newborns experience. Babies may also develop an enlarged liver or spleen as those organs work overtime to compensate for the blood cell loss.
In the most severe cases, the baby can develop a condition called hydrops fetalis, where fluid accumulates throughout the body’s tissues and organs, including around the heart and lungs. This condition carries a mortality rate estimated above 50%. If bilirubin levels rise too high after birth and go untreated, the compound can cross into the brain and cause permanent neurological damage, including cerebral palsy, hearing loss, and intellectual disability.
How Screening Works
Every pregnant person has their blood type and Rh status checked at their first prenatal visit after 8 weeks of gestation. This blood draw also includes an antibody screen, which checks whether your body has already produced antibodies against Rh-positive blood from a previous pregnancy, miscarriage, or blood transfusion.
If you’re Rh negative, a newer option can help determine whether prevention is even necessary. Cell-free fetal DNA screening, a blood test that analyzes fragments of the baby’s DNA circulating in your bloodstream, can identify the baby’s Rh type without any invasive procedure. If the baby turns out to be Rh negative like you, there’s no incompatibility and no risk, so treatment isn’t needed.
How RhoGAM Prevents the Problem
The standard prevention is an injection called Rh immunoglobulin, most commonly known by the brand name RhoGAM. It works by neutralizing any Rh-positive fetal blood cells that have entered your bloodstream before your immune system has a chance to recognize them and form its own antibodies. Think of it as clearing the evidence before your immune system can react.
The standard schedule involves two doses: one given between weeks 26 and 28 of pregnancy, and a second within 72 hours after delivery if the baby is confirmed Rh positive. With this schedule, the chance of sensitization drops to less than 1%. If the postpartum dose is accidentally missed, it should be given as soon as possible, ideally still within that 72-hour window.
You may also need a dose of RhoGAM earlier in pregnancy if anything occurs that could cause fetal and maternal blood to mix. This includes miscarriage, ectopic pregnancy, amniocentesis, chorionic villus sampling, or abdominal trauma. The standard dose contains 300 micrograms of anti-Rh antibodies, though a smaller 50-microgram dose exists for certain situations early in pregnancy.
What This Means for Your First vs. Later Pregnancies
A first pregnancy with Rh incompatibility rarely causes harm to the baby, because the initial immune response produces antibodies too large to reach the fetus. The real danger lies in subsequent pregnancies if sensitization has already occurred. This is exactly why the prevention schedule targets the first pregnancy so aggressively: the goal is to stop sensitization from ever happening in the first place.
If you’ve already been sensitized (your antibody screen comes back positive), RhoGAM can no longer help because your immune system has already learned to produce anti-Rh antibodies on its own. In that case, your pregnancy will be monitored more closely with repeat antibody level checks and specialized ultrasounds to watch for signs of fetal anemia. Higher antibody levels correlate with greater risk to the baby, and very high levels may require early delivery or other interventions.
The key takeaway is that Rh-negative status in pregnancy is one of the most successfully managed complications in modern obstetrics. Before RhoGAM became available in the late 1960s, hemolytic disease of the newborn was a leading cause of infant death. Today, with routine screening and prevention, severe cases are rare.